Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Viking Therapeutics reports Q1 loss, confident in upcoming studies

Viking Therapeutics is well-funded with a cash balance of $406 million pro forma. The company's focus on promising programs and confidence in upcoming data for VK2735's oral formulation study present opportunities for growth. However, challenges exist in achieving exposure levels and managing expenses.

Viking Therapeutics Reports Positive Clinical Data and Successful Financing

Viking Therapeutics reported positive clinical data and successful financing. They are focused on aggressive clinical development of internal programs and provided detailed updates on their clinical programs. The company faces challenges related to formulation, potential partnerships, and competition, while also anticipating opportunities for abstract submissions and further study developments.

Viking Therapeutics Reports Improved Financials and Promising Clinical Progress

Viking's financials improved, with a strong cash position. VK2735 and VK2809 show promise in obesity and NASH treatment, respectively. However, challenges exist in formulation and expansion into NASH.

Viking Therapeutics Reports Strong Financial Position and Positive Clinical Trial Results

Viking Therapeutics ended 2023 with a strong balance sheet and highlighted positive clinical trial results. Despite financial and regulatory challenges, the company remains open to partnerships and is poised to report key trial results in 2024, presenting opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Intercept Pharma

Vir Biotechnology

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

3 Biotech Stocks That Are too Cheap to Ignore

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q4 2021 Results - Earnings Call

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended December 31, 2021, and Other Recent Events: "The past year was a productive time for Viking as we continued to make progress with our two most advanced clinical programs and further expanded our clinical pipeline with the addition of an important new program," said Brian Lian, Ph.D.

Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 7, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference.

Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Viking and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX

SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2021, after the market close on Wednesday, February 9, 2022. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA

The clinical trial has been halted by the FDA for now, pending the submittal of a preclinical study.

Why Viking Therapeutics Stock Got Mashed on Monday

The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) fell by over 14% during intraday trading today. This is why it happened.

Viking Therapeutics Stock (VKTX): Why The Price Substantially Went Down Today

The FDA has placed a clinical hold on Viking Therapeutics Inc's (NASDAQ: VKTX) Phase 1b trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD).  The FDA has requested an additional preclinical study before continuing the Phase 1b study of VK0214 in X-ALD, not due to any findings from ongoing or previously completed studies.

Viking Therapeutics' Early Stage Trial On FDA Hold In Rare Metabolic Disorder

SAN DIEGO , Jan. 24, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD) has been placed on clinical hold by the United States Food and Drug Administration (FDA).  The FDA has requested an additional preclinical study prior to continuing the Phase 1b study of VK0214 in X-ALD.

Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is in development for the potential treatment of various metabolic disorders.

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist

CRISPR Therapeutics

Ultragenyx Pharmaceutical

Marinus Pharmaceuticals

Relmada Therapeutics Inc

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

5 Sizzling ‘Strong Buy' Analyst Biotechnology Picks for 2022

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C.

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 24.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Viking Therapeutics, Inc. (VKTX)

The average of price targets set by Wall Street analysts indicates a potential upside of 225.8% in Viking Therapeutics, Inc. (VKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Viking Therapeutics, Inc. (VKTX) Could Surge 226%: Read This Before Placing a Bet

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2021 Virtual Healthcare Conference.

Viking Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Viking Therapeutics, Inc. (VKTX) Now Trades Above Golden Cross: Time to Buy?

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended September 30, 2021 and Other Recent Events: "The third quarter was a busy and productive time for Viking as we continued to make progress with our lead clinical programs targeting NASH and X-ALD, and expanded our pipeline with an additional program for metabolic disorders," stated Brian Lian, Ph.D.

Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

The consensus price target hints at a 204.1% upside potential for Viking Therapeutics, Inc. (VKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Viking Therapeutics, Inc. (VKTX)? Wall Street Analysts Think 204%

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors at ObesityWeek® 2021. The presentations highlight the effects of treatment on body weight and metabolic profile in diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle, the GLP-1 agonist semaglutide, or the dual GLP-1/GIP agonist tirzepatide.

Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021

SAN DIEGO, Oct. 27, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2021, after the market close on Wednesday, November 3, 2021. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

Viking Therapeutics to Report Financial Results for Third Quarter 2021 on November 3, 2021

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society. Results from studies in diet induced obese (DIO) mice will be featured in two poster presentations at the conference, which is being held virtually November 1-5, 2021.

Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021

SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of H.C.

News for Viking Therapeutics Stock (VKTX)